NCT03435770 is a NA clinical trial of EUSRA RFA needle in Pancreatic Cancer, sponsored by Singapore General Hospital.

Who is sponsoring NCT03435770?

NCT03435770 is sponsored by Singapore General Hospital.

What drugs are being tested in NCT03435770?

Interventions in NCT03435770: EUSRA RFA needle.

What condition does NCT03435770 study?

NCT03435770 studies Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma.

Is NCT03435770 still recruiting?

NCT03435770 is currently status unknown. Last updated 20 February 2018.

Last reviewed 2018-02-20 · How we verify

NCT03435770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms

Status unknown NA Last updated 20 February 2018

What this trial tests

NA trial testing EUSRA RFA needle in Pancreatic Cancer in 10 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 September 2019

1 September 2019

Quick facts

Lead sponsor	Singapore General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 March 2018
Primary completion	1 September 2019
Estimated completion	1 September 2019
Sites	1 location across Singapore

Drugs / interventions tested

EUSRA RFA needle

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →

Sponsor

Singapore General Hospital

Who can join

Adults 21 to 99, any sex, with Pancreatic Cancer or Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the safety and efficacy of new ablation catheter developed by MEDICAL TAEWOONG for the treatment of pancreatic neoplasm (pancreatic adenocarcinoma or neuroendocrine tumour). The ablation is performed using EUSRA needle and radio frequency waves under ultrasound imaging. The subject who will be recruited into this study are patients who are deemed as non-surgical candidates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.
Moond V, Maniyar B, Harne PS, Bailey-Lundberg JM, et al · · 2024 · cited 6× · PMID 39351436 · DOI 10.37349/etat.2024.00263

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Singapore General Hospital trials

Trials by the same sponsor.

NCT07452159 — Diabetes In Asians at Risk in Youth · not yet recruiting
NCT07527247 — Improving Vaccine Protection for Older Adults · Phase 2 · recruiting
NCT07533188 — Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomize · NA · recruiting
NCT07042061 — Trial of Mobile External Defibrillator for Out-of-hospital Cardiac Arrest in Singapore. · NA · not yet recruiting
NCT07099040 — Community-based Multi-domain Intervention to Detect and Delay Cognitive Decline in Community-dwelling Older Adults: A Pi · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03435770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Singapore General Hospital
Last refreshed: 20 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03435770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing